MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Vaccine

Volumn 35, Issue 12, 2017, Pages 1586-1589

  Coleman, Christopher M ^a   Venkataraman, Thiagarajan ^a   Liu, Ye V ^b   Glenn, Gregory M ^b   Smith, Gale E ^b   Flyer, David C ^b   Frieman, Matthew B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NOVAVAX INC   (United States)

Author keywords

Coronavirus; MERS CoV; Mouse model; Nanoparticle vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; NEUTRALIZING ANTIBODY; RECOMBINANT MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS SPIKE PROTEIN NANOPARTICLE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CORONAVIRUS INFECTION; DISEASE MODEL; GENETICS; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 85013449789     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.02.012     Document Type: Article

References (19)

1. [1] Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Eng J Med 367 (2012), 1814–1820.
2. [2] Uyeki, T.M., Erlandson, K.J., Korch, G., O'Hara, M., Wathen, M., Hu-Primmer, J., et al. Development of medical countermeasures to Middle East respiratory syndrome coronavirus. Emerg Infect Dis, 22, 2016.
3. [3] Excler, J.L., Delvecchio, C.J., Wiley, R.E., Williams, M., Yoon, I.K., Modjarrad, K., et al. Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015. Emerg Infect Dis, 22, 2016.
4. [4] Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Muller, M.A., Dijkman, R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
5. [5] Wang, Q., Wong, G., Lu, G., Yan, J., Gao, G.F., MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Res 133 (2016), 165–177.
6. [6] Coleman, C.M., Liu, Y.V., Mu, H., Taylor, J.K., Massare, M., Flyer, D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32 (2014), 3169–3174.
7. [7] Coleman, C.M., Matthews, K.L., Goicochea, L., Frieman, M.B., Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 95 (2014), 408–412.
8. [8] Cockrell, A.S., Peck, K.M., Yount, B.L., Agnihothram, S.S., Scobey, T., Curnes, N.R., et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol 88 (2014), 5195–5199.
9. [9] Peck, K.M., Cockrell, A.S., Yount, B.L., Scobey, T., Baric, R.S., Heise, M.T., Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection. J Virol 89 (2015), 4696–4699.
10. [10] Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S.S., Fett, C., Gale, M.J. Jr., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 111 (2014), 4970–4975.
11. [11] Channappanavar, R., Lu, L., Xia, S., Du, L., Meyerholz, D.K., Perlman, S., et al. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis 212 (2015), 1894–1903.
12. [12] Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA 112 (2015), 10473–10478.
13. [13] Luke, T., Wu, H., Zhao, J., Channappanavar, R., Coleman, C.M., Jiao, J.A., et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med, 8, 2016, 326ra21.
14. [14] Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T., et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 13 (2016), 180–190.
15. [15] Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 25 (2015), 1237–1249.
16. [16] Wirblich, C., Coleman, C.M., Kurup, D., Abraham, T.S., Bernbaum, J.G., Jahrling, P.B., et al. One-health: a safe, efficient dual-use vaccine for humans and animals against MERS-CoV and Rabies virus. J Virol, 2016.
17. [17] Coleman, C.M., Frieman, M.B., Growth and quantification of MERS-CoV infection. Curr Protoc Microbiol, 37, 2015 15E 2 1-9.
18. [18] Lovgren Bengtsson, K., Morein, B., Osterhaus, A.D., ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccin 10 (2011), 401–403.
19. [19] Smith, G., Raghunandan, R., Wu, Y., Liu, Y., Massare, M., Nathan, M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE, 7, 2012, e50852.